» Authors » Janis Homewood

Janis Homewood

Explore the profile of Janis Homewood including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 417
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
de Wreede L, Watson M, van Os M, Milligan D, van Gelder M, Michallet M, et al.
Am J Hematol . 2013 Oct; 89(2):174-80. PMID: 24123244
In chronic lymphocytic leukemia (CLL) medical progress is driven by clinical studies with relapse-free survival (RFS) as the primary endpoint. The randomized EBMT-Intergroup trial compared high-dose therapy and autologous stem...
2.
Owen J, Ashton A, Bliss J, Homewood J, Harper C, Hanson J, et al.
Lancet Oncol . 2006 Jun; 7(6):467-71. PMID: 16750496
Background: Standard curative schedules of radiotherapy to the breast deliver 25 fractions of 2.0 Gy over 5 weeks. In a randomised trial, we tested whether fewer, larger fractions were at...
3.
Watson M, Homewood J, Haviland J, Bliss J
Eur J Cancer . 2005 Aug; 41(12):1710-4. PMID: 16098457
The possibility that psychological response within a few weeks of a breast cancer diagnosis can influence the outcome of the disease is a contentious issue. Psychological response, including helplessness/hopelessness, fighting...
4.
Andreassen C, Alsner J, Overgaard J, Herskind C, Haviland J, Owen R, et al.
Radiother Oncol . 2005 May; 75(1):18-21. PMID: 15878096
Recent studies suggest that normal tissue radiosensitivity is influenced by single nucleotide polymorphisms (SNPs) in certain genes. In order to seek a confirmation of these findings, this study investigated SNPs...
5.
Yarnold J, Ashton A, Bliss J, Homewood J, Harper C, Hanson J, et al.
Radiother Oncol . 2005 May; 75(1):9-17. PMID: 15878095
Background And Purpose: Unlike squamous carcinomas, breast adenocarcinoma may be as sensitive to fraction size as late dose-limiting normal tissues. If so, fewer larger fractions would be as safe and...
6.
Homewood J, Watson M, Richards S, Halsey J, Shepherd P
Hematol J . 2003 Jul; 4(4):253-62. PMID: 12872150
Treatment of chronic myeloid leukaemia (CML) with IFN-alpha (IFN) is known to confer significant survival benefit, but the drug's impact on quality of life (QoL) in CML is unclear. We...